DENVER, May 1 /PRNewswire-FirstCall/ -- Scientists from Accelr8
Technology Corporation (Amex: AXK) presented a combined technical poster at
the 38th annual Oak Ridge Conference, entitled "Pushing the Technology
Envelope III: The Next Generations of Diagnostic Testing" on April 21. The
poster title was "Identification and growth rate quantitation of individual
bacterial clones using a novel microfluidic concentration device." The
poster summarized methods and results of laboratory work that demonstrate
the performance of the analyses being designed into the company's
BACcelr8r(TM) rapid bacterial analysis system.
The research used the company's patent-pending Quantum Microbiology(TM)
methods for analyzing individually identified cells. The results included
data from experimental models for each of seven key operating
1. Specimen preparation
2. Bacterial concentration and surface immobilization
3. Bacterial viability after immobilization
4. Species immuno-identification
5. Quantitative growth rate measurement
6. Growth rate comparability to standard methods
7. Quantitative antibiotic kill rate measurement.
The conference was sponsored by the American Association for Clinical
Chemistry (AACC, www.aacc.org). The AACC is a large, US-based international
scientific/medical society of clinical laboratory professionals,
physicians, research scientists and other individuals engaged in
science-related clinical laboratory disciplines. The Oak Ridge Conference
is the AACC venue for new science and technology in emerging diagnostics.
The poster presentation represents the company's first disclosure of
Quantum Microbiology principles to the scientific and clinical laboratory
communities. According to David Howson, Accelr8's president, "this research
shows that our methods produce results comparable to those from standard
methods, but in a much shorter time. The time to results are well within
our stated goals of two hours for identification and counts, and eight
hours for testing antibiotic resistance. Under favorable conditions,
standard methods require at least 24 hours."
The reported research used standard bacterial reference strains and
studied each step in the analytical process. "Our next steps include
integrating all of the analytical steps into a single continuous
procedure," Howson continued. "We also will also proceed to studies using
known concentrations of bacteria in biological fluids. These studies will
help to demonstrate our ability to eliminate culturing and isolation, and
analyze bacteria extracted directly from a specimen."
In May, the company will present a poster at the General Meeting of the
American Society for Microbiology (ASM, www.asm.org). The ASM is the
leading American professional society for microbiologists. The poster will
studies on a challenging type of antibiotic resistance analysis that
has proven difficult to implement in standard automated systems.
"These presentations are the first in our planned pipeline of
scientific and clinical publications," added Howson. "Hospital-acquired
pneumonia is the number one infectious cause of mortality in the ICU. Rapid
antibiotic resistance analysis would represent a breakthrough in addressing
this problem. We intend ultimately to validate the BACcelr8r as achieving
this analytical goal, and these presentations offer the first evidence that
this will be possible."
Accelr8 Technology Corporation (www.accelr8.com) is a developer of
innovative materials and instrumentation for advanced applications in
medical instrumentation, basic research, drug discovery, and bio-detection.
In addition to its microarraying products, Accelr8 is also developing a
rapid clinical pathogen platform, the BACcelr8r(TM), based on its
innovative surface coatings, assay processing, and detection technologies.
Safe Harbor for Forward-Looking Statements
Certain statements in this news release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. Statements regarding future prospects and developments are
based upon current expectations and involve certain risks and uncertainties
that could cause actual results and developments to differ materially from
the forward-looking statement, including those detailed in the company's
filings with the Securities and Exchange Commission. Accelr8 does not
undertake an obligation to publicly update or revise any forward-looking
statements, whether as a result of new information or future events.
SOURCE Accelr8 Technology Corporation